Showing 1271-1280 of 2910 results for "".
Caregiver Screening Tools for Agitation in Alzheimer’s Disease
https://practicalneurology.com/programs/cme/caregiver-screening-tools-for-agitation-in-alzheimers-disease/28795/Tune in to learn about diagnosing and treating agitation in Alzheimer’s disease in primary care and long-term care settings.Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD
https://practicalneurology.com/programs/cme/safety-efficacy-and-black-box-warnings-challenges-associated-with-off-label-treatments-of-aad/27099/Tune in to learn about diagnosing and treating agitation in Alzheimer’s disease in primary care and long-term care settings.Team Approach: Enhancing Collaboration in AAD Management
https://practicalneurology.com/programs/cme/team-approach-enhancing-collaboration-in-aad-management/27097/Tune in to learn about diagnosing and treating agitation in Alzheimer’s disease in primary care and long-term care settings.Navigating Therapy: Exploring FDA-Approved Treatments for Effective AAD Care
https://practicalneurology.com/programs/cme/navigating-therapy-exploring-fda-approved-treatments-for-effective-aad-care/27101/Tune in to learn about diagnosing and treating agitation in Alzheimer’s disease in primary care and long-term care settings.Pay for Performance: Understanding and Preparing for MIPS
https://practicalneurology.com/columns/practice-management/pay-for-performance-understanding-and-preparing-for-mips/30418/As a new reimbursement model is set to unveil, physicians will have a tight window to prepare their practices to begin reporting in 2017.Board Re-Certification: Reform or Reboot
https://practicalneurology.com/columns/practice-management/board-re-certification-reform-or-reboot/30542/A neurologist has been leading the charge to reform MOC in neurology. He talked to Practical Neurology® about the issue.Rising Drug Prices and the Cost of Care: What Can Physicians Do?
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/rising-drug-prices-and-the-cost-of-care-what-can-physicians-do/30327/The multiple sclerosis drug market offers a snapshot of a growing problem. Physicians should speak out on behalf of the specialty and their patients.Preferred Treatment: The Changing Economics of Multiple Sclerosis Care
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/preferred-treatment-the-changing-economics-of-multiple-sclerosis-care/30486/By deciding which drugs are “preferred,” insurance companies are reducing the practice of evidence-based medicine to a series of economic choices.NeuroAdvocacy: Why Lobbying Matters
https://practicalneurology.com/columns/practice-management/neuroadvocacy-why-lobbying-matters/30328/Advocating for patients and the specialty is a powerful way for physicians to make their voices heard.Precision Medicine: How Advancements in Imaging, Delivery, and Patient Comfort are Increasing the Relevance of Deep Brain Stimulation
https://practicalneurology.com/diseases-diagnoses/imaging-testing/precision-medicine-how-advancements-in-imaging-delivery-and-patient-comfort-are-increasing-the-relevance-of-deep-brain-stimulation/30382/